Conclusion GLP-1 and its receptor agonists represent a significant advancement in the treatment of metabolic disorders
Think of it this way: before retatrutide, consuming one standard drink might produce a peak BAC of 0.02% that returns to baseline in 90 minutes
Biguanide MC001, a dual inhibitor of OXPHOS and glycolysis, shows enhanced antitumor activity without increasing lactate production
Furthermore, we used propensity score matching to minimize confounding
Claim Strength Matrix for Skin, Hair, and Healing Claims Skin aging claims are moderate when limited to topical cosmetic outcomes, wound-healing claims are context-dependent because evidence includes both human diabetic-ulcer research and animal models, and hair growth claims remain preliminary or indirect [2], [3], [6], [13]
Accessed 12 Nov 2025 10.1111/apt.12809